Hospitals' Net Revenue Leakage Increases 25% Due to Denied Claims
Hospitals experienced a 25% jump in net‑revenue leakage in 2025, with total losses climbing to roughly $48 billion versus $38.6 billion in 2024. The surge stemmed mainly from clinical claim denials, especially for missing prior authorizations and questioned medical necessity. Medicaid accounted for the highest denial rates, while Medicare Advantage plans saw denial frequencies more than twice those of traditional Medicare. Commercial insurers contributed disproportionately to revenue loss because of their higher reimbursement rates.
Human Factors in Safety-Critical Environments: From Operating Rooms to Urban Roads
The article argues that human factors—cognitive load, stress, fatigue, and physiological limits—shape outcomes in any safety‑critical setting, from operating rooms to urban streets. It highlights how healthcare has long used checklists, protocols and fatigue‑management programs to curb errors, and shows...
Commure Launches AI-Powered Speech-to-Cursor Dictation Tool for Clinical Workflows
Commure has unveiled Commure Dictation, an AI‑powered speech‑to‑cursor extension that turns the company’s Ambient mobile app into a wireless microphone for clinicians. The tool eliminates the need for costly, dedicated dictation hardware and enables physicians to dictate notes, messages, and referrals...
AI Tools Simplify Complex Care Data, but Risks Persist
AI-driven platforms are increasingly helping patients decode complex medical records, offering simplified visualizations and personalized insights. However, experts like Leigh Burchell of Altera Digital Health warn that many of these tools lack HIPAA compliance, exposing sensitive health data to breaches....
Drug Substance Maker Raises Prices Due to Energy Crisis; SpectronRX Gets $85M
BASF Pharma Solutions announced a 12% price increase on its active pharmaceutical ingredients (APIs) as soaring energy costs, driven by the ongoing Middle East conflict, strain its supply chain. The hike affects generic manufacturers and could push drug prices higher...
Lipocine's Postpartum Depression Drug Fails; AstraZeneca Claims Liver Cancer Win
Lipocine reported top‑line Phase 3 data for its postpartum depression candidate LPCN‑1154, revealing no statistically significant improvement over placebo and prompting a 77% plunge in its shares. The Utah‑based biotech’s safety profile was acceptable, but efficacy shortfalls undermine its commercial prospects....
Debunked Episode 25: Sutter Health’s Allina Health Acquisition Strategy, a Deep Dive on Doctronic
Sutter Health announced a cross‑border acquisition of Minnesota‑based Allina Health, marking a strategic push into health‑technology and AI. The deal gives Sutter access to Allina’s medtech engineering talent while providing Allina with the scale needed to compete against larger systems...
Q&A: Empowerment Over Information – Rethinking Patient Education
The piece argues that the flood of digital health information has outpaced patients' ability to evaluate and apply it, leaving many feeling overwhelmed rather than empowered. It highlights that clinicians often provide data without guiding patients toward trustworthy sources, and...
HNSCC Market Is Expected to Reach to $4.5bn Across 8MM by 2034
GlobalData projects the head and neck squamous cell carcinoma (HNSCC) therapeutics market to grow from $2.0 bn in 2024 to $4.5 bn by 2034, reflecting an 8.4% compound annual growth rate. Immune checkpoint inhibitors (ICIs) dominate, accounting for 69% of 2024 sales...
AI-Powered Cohorting Is Quietly Reshaping How Real-World Evidence Gets Built
AI‑powered cohorting is redefining how real‑world evidence is generated by replacing manual SQL‑driven processes with modular, workflow‑based automation. The new approach decomposes cohort construction into discrete steps—intent interpretation, clinical concept mapping, temporal reasoning, execution, validation, and explanation—each handled by specialized...
Trump Is Preparing 100% Tariffs on some Drugmakers, Documents Show
President Donald Trump is preparing to announce 100% tariffs on select pharmaceutical products, according to a draft memo obtained by Endpoints News. The tariffs would apply to a limited group of drugmakers, targeting high‑priced brand‑name drugs rather than the entire...
DOJ Cracks Down On Unfair Contracts With New Lawsuit Against NewYork-Presbyterian
The U.S. Department of Justice has filed an antitrust lawsuit against NewYork‑Presbyterian Hospital, accusing it of using “all‑or‑nothing” payer contracts that force insurers to include every NYP facility in their networks. The complaint says the practice blocks lower‑cost plans, limits...
New Opioid Painkiller Has Surprisingly Few Side Effects
Scientists have identified a new opioid, N-desethyl‑fluornitrazene (DFNZ), derived from the long‑abandoned nitazene class, that delivers strong pain relief in rodents without causing respiratory depression or high addiction potential. The molecule acts as a μ‑opioid‑receptor superagonist yet exits the brain...
STAT+: Lilly’s Obesity Pill Enters the Oral GLP-1 Game, Novo Responds
The FDA approved Eli Lilly’s oral GLP‑1 obesity pill orforglipron, marking the first FDA‑cleared oral weight‑loss drug. The approval puts Lilly into direct competition with Novo Nordisk, which is developing its own oral GLP‑1 candidate. Simultaneously, a draft Trump administration order could...
Healthcare Affordability Requires a Collective Effort, Industry Leaders Say
At the ViVE health‑tech conference, HFMA‑led panelists warned that healthcare affordability is an urgent, collective challenge. A Gallup poll shows 29 % of Americans now view cost as the top concern, up from 23 % a year earlier. Providers plan to spend...
To Bend the Curve on Heart Disease, Prevention Must Move Upstream
Heart disease remains the leading cause of death in the United States, yet preventive cardiovascular screening is scarce and confined to specialist settings. Advanced imaging tools can detect risk early, but most primary care visits only include basic vitals, leaving...
GE HealthCare Receives FDA Clearance for True Definition DL CT Image Reconstruction Technology
GE HealthCare has obtained FDA 510(k) clearance for its True Definition DL CT image reconstruction technology. The AI‑driven tool enhances spatial resolution in high‑contrast regions such as lungs, musculoskeletal tissue, and the inner ear, delivering ultra‑high‑resolution images in under one...
Rural America Doesn’t Need Another Framework … It Needs Care by September 2026
The CMS Rural Health Transformation Program will undergo its first performance review in September 2026, linking future funding to measurable patient outcomes. While policymakers debate long‑term frameworks, rural communities are already facing acute mental‑health bed shortages, with thousands forced into...
The Rollercoaster Ride Stopps and Danish IO Biotech Goes Bust
Copenhagen‑based IO Biotech, a cancer immunotherapy firm, saw its flagship melanoma vaccine Cylembio miss the primary endpoint in a Phase III trial, prompting the FDA to advise against filing for approval. The regulatory setback left the company with insufficient runway, as...
Merck Receives the EC Approval for Keytruda, Plus CT ± Avastin to Treat PD-L1+ Pt-Resistant Ovarian Carcinoma
The European Commission has granted approval for Merck’s Keytruda (pembrolizumab) combined with paclitaxel, with or without Avastin, to treat PD‑L1‑positive, platinum‑resistant ovarian, fallopian‑tube or primary peritoneal carcinoma. The indication covers adults who have received one or two prior systemic regimens...
Dental Implants in 2026: What Patients and Providers Need to Know
Dental implants have transitioned from a last‑resort option to the standard of care for single‑tooth replacement, driven by higher success rates and bone‑preserving benefits. Advances in cone‑beam imaging and guided‑surgery software now deliver pinpoint accuracy, shortening procedures and reducing complications....
Politics Should Not Determine Who Gets Admitted To Medical School
The Department of Justice, acting on a Trump administration executive order, has opened investigations into the admission practices of Ohio State University, Stanford University and UC San Diego medical schools, demanding seven years of applicant data and threatening loss of...
How Trump’s War in Iran Is Scrambling Pharma’s Shipping Options
U.S. and Israeli strikes on Iran have tightened the Strait of Hormuz blockade, cutting off a key east‑west artery that handles roughly 10% of global pharmaceutical shipments. Temperature‑controlled ingredients, which make up about 20% of those flows, are especially vulnerable,...
Wave 4 & 5 - ECR Health Care Complex / FAAB
Wave 4 and 5 of the ECR Health Care Complex in Sopot, Poland, are slated for completion in 2025, adding an analytical laboratory, outpatient clinic, day‑surgery hospital, and specialist hospital to the campus. The development reclaims five hectares of flood‑prone brownfield land...
Dominican National Pleads Guilty to Illegal Reentry, Misuse of Social Security Number, and Benefits Fraud
A Dominican national illegally residing in the United States pleaded guilty in Rhode Island federal court to a decade‑long scheme that used stolen identities to obtain roughly $75,000 in Medicaid, SNAP and unemployment benefits. Jesus Matos Perez admitted to illegal...
Marathon Health’s Newly Appointed CEO Looks to Maintain a Flexible Model
Marathon Health appointed Chris Pricco as chief executive officer, succeeding co‑founder Jeff Wells. Pricco said the company will keep its flexible advanced primary‑care (APC) model, tailoring on‑site or network clinics to each employer’s workforce. He highlighted three priorities: flexible service...
Restor3d Launches Aeros Modular Stem System
restor3d announced the full commercial launch of its Aeros Modular Stem System for total ankle replacement, becoming available in the United States on April 2, 2026. The system, part of the Kinos Total Ankle portfolio, features 3D‑printed porous tibial and...
Comprehensive Management of Shoulder Injuries Through Surgical Intervention and Specialist Care
Shoulder injuries, ranging from rotator cuff tears to frozen shoulder, demand a coordinated care pathway that begins with precise diagnosis and often starts with conservative therapy. When non‑surgical measures such as physical therapy and anti‑inflammatories fail, minimally invasive arthroscopic techniques...
Supporting Oral Health at Every Stage with Family Dentistry and Restorative Treatments
Maintaining oral health throughout life demands a proactive blend of preventive care and restorative treatments. Family dentists deliver continuity, offering routine exams, cleanings, fluoride applications, and early diagnosis for children, adults, and seniors. Modern restorative options—fillings, crowns, bridges, and especially...
A New Implant Aims to Rewire the Brain to Help Stroke Patients
Epia Neuro, a San Francisco startup, unveiled a brain‑computer interface paired with a motorized glove to restore hand function in stroke patients. The disk‑shaped implant sits under the skull, captures neural intent from undamaged brain regions, and translates it via...
Biocytogen and Sihuan Pharmaceutical Partner to Discover Novel Therapeutics in Multiple Indications
Biocytogen and China’s Sihuan Pharmaceutical have signed a strategic partnership to co‑develop novel antibody therapeutics across several disease areas, including obesity. The deal merges Biocytogen’s fully human antibody discovery platform—featuring target‑humanized mouse models, in‑vivo efficacy systems, and an AI‑driven sequence...
ACC 2026: Meta-Analysis Supports CagriSema as Superior First-Line Therapy in Obesity
At the ACC 2026 meeting, a Bayesian network meta‑analysis of 2,803 overweight and obese adults showed that the fixed‑dose combination CagriSema outperformed its components, cagrilintide and semaglutide 2.4 mg, across all efficacy measures. CagriSema delivered the greatest absolute and percent weight...
Why Do Black Women Have Worse IVF Outcomes?
A University of Pennsylvania analysis of more than 246,000 IVF cycles found that Black women experience a live‑birth rate of about 45%, compared with roughly 60% for white women. Despite responding slightly better to ovarian‑stimulation drugs and producing high‑quality embryos,...
Cyber-Physical Security Gaps Demand Attention, Health-ISAC’s 2025 Exercise Series Finds
Health‑ISAC’s 2025 resilience exercise series revealed persistent gaps in coordinating cyber and physical security teams across seven simulated ransomware‑plus‑intrusion tabletop drills. Participants repeatedly reported fragmented communication, delayed escalation, and insufficient joint response procedures. The after‑action report distilled twelve priority observations,...
Rhythm Posts First FDA Approval for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity, covering adults and children aged four and older. The decision follows the Phase 3 TRANSCEND trial, which demonstrated an 18.4% mean BMI reduction versus placebo...
AstraZeneca Reports the P-III (EMERALD-3) Trial Data on Imfinzi Combination + TACE in Unresectable Hepatocellular Carcinoma
AstraZeneca presented interim data from its Phase III EMERALD-3 trial, evaluating a single priming dose of Imjudo (300 mg) plus Imfinzi (1500 mg) followed by quarterly Imfinzi and transarterial chemoembolisation (TACE) with or without lenvatinib in 760 patients with unresectable hepatocellular carcinoma...
Trump's Surgeon General Nominee Caught in GOP Crossfire over MAHA
President Trump’s nominee for surgeon general, health‑coach Casey Means, remains stalled in the Senate as key Republican senators refuse to back her. Means, an influencer with an expired medical license, faces criticism over her lack of public‑health experience and controversial...
Scientists Cured Type 1 Diabetes in Mice by Creating a Blended Immune System
Scientists have cured type 1 diabetes in mice by creating a blended, or chimeric, immune system that tolerates transplanted insulin‑producing cells without lifelong immunosuppression. The protocol combines donor bone‑marrow stem cells, islet cells, low‑dose radiation, antibodies and the drug baricitinib, allowing...
‘This Is an Overlooked Catastrophe’: Why Do so Many Hospitals Not Accept ...
A widening crisis is emerging as an increasing number of hospitals across the United States refuse to accept Medicare Advantage (MA) plans for oncology services. The trend is not limited to Florida; major academic and community hospitals nationwide are tightening...
Postbiotic Supplement May Protect Against Childhood Dental Caries: RCT
A randomized pilot study in Kraków gave 72 preschoolers chewable tablets containing 20 mg of heat‑inactivated Lactobacillus salivarius HM‑6 Paradens for two weeks. Children receiving the postbiotic showed a marked drop in Streptococcus mutans and a rise in beneficial Lactobacillus spp.,...
What the Research Actually Says About Home Modifications and Fall Prevention
Falls among adults 65+ are a leading cause of injury‑related hospitalization, with the majority occurring at home. Robust research, including a Cochrane review of 159 trials, shows that targeted home modifications—especially in bathrooms and stairways—significantly reduce fall incidence. Interventions are...
US Scientists Sequence 1,000 Genomes From Measles, a Disease Long Eliminated With Vaccines
The CDC has posted its first batch of whole‑genome sequences from roughly 1,000 measles viruses collected in 2025‑2026, marking the United States' inaugural use of large‑scale genomic surveillance for the disease. The data will allow researchers to trace transmission pathways...
APOE4 Variant Linked to Greater Neurological Damage in Multiple Sclerosis
A UK Biobank study of 188 multiple sclerosis patients reveals that carriers of the APOE4 gene variant experience significantly greater neurodegeneration than non‑carriers. APOE4 carriers showed higher blood levels of neurofilament light chain and glial fibrillary acidic protein, more extensive...
Actinogen Treats First Patient in XanaMIA Trial for Alzheimer’s
Actinogen Medical has begun treating the first participant in the open‑label extension (OLE) of its Phase IIb/III XanaMIA trial for Alzheimer’s disease. The OLE allows eligible U.S. and Australian subjects to receive Xanamem 10 mg daily for up to 25 months, collecting...
This Week in European MedTech and HealthTech: 2nd April 2026
European MedTech entered a phase of regulatory convergence and digital integration in the week of March 26‑April 2, 2026. BD launched its Pyxis™ Pro dispensing system and Incada™ Connected Care platform on the AWS European Sovereign Cloud, addressing EU data‑sovereignty rules. The European Commission...
Cogent Biosciences Reports US FDA’s NDA Submission of Bezuclastinib for Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences announced that the U.S. FDA has received a New Drug Application for bezuclastinib under the Real-Time Oncology Review program, targeting gastrointestinal stromal tumor patients who have progressed after imatinib. The Phase III PEAK trial, comparing bezuclastinib plus sunitinib to...
Recent Billing Code Changes Wreaking Havoc for Radiation Oncologists, New Survey Finds
On Jan. 1, 2026, the CPT Editorial Panel introduced three-tier radiation‑therapy billing codes, eliminating code 77014 and adding a professional‑component code. A survey of 160 ASTRO members shows more than two‑thirds experiencing payment drops of 10% or higher, with some cuts exceeding...
Annovis Publishes Historical Review of Buntanetap
Annovis released a historical review of its investigational drug Buntanetap in The Scientist, charting its evolution from a 19th‑century execution poison to a modern candidate for Alzheimer’s and Parkinson’s disease. The article details discovery, mechanism elucidation, chemical optimization, and progression...
Humanaut to Open Dallas Clinic, Launches Founding Membership Presale
Humanaut announced the opening of its first flagship clinic in Dallas, Texas, alongside a founding membership presale. The clinic will deliver metabolic profiling, continuous glucose monitoring, and AI‑driven health coaching under a $5,000 annual membership. The presale targets $10 million to...
How Acclaim Autism Cut Patient Onboarding From Six Months to Four Days with Appian
Acclaim Autism, a Philadelphia‑based autism‑care provider, used Appian’s low‑code automation to shrink patient onboarding from six months to four days. Insurance denial rates fell from 80% to 5%, and monthly intake rose from three to 47 patients, a fifteen‑fold increase....